Safety of MT-401-OTS in Patients With Relapsed AML or MDS
Clinical trial NCT06552416 · RECRUITING
Trial details
- NCT number
- NCT06552416
- Sponsor
- Marker Therapeutics, Inc.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-16
- Primary completion
- 2029-09-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.